Sunday, July 12, 2026

TGA / PMDA / NMPA · Asia-Pacific

enterovirus — TGA / PMDA / NMPA regulatory status

enterovirus regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.

Status snapshot

Status
NMPA clinical trials
Structured fields
4

Regional decision snapshot — NMPA: clinical trials.

Linked evidence on this spoke: 7 published clinical programs and 5 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
NMPA China clinical trials Evidence

Linked clinical programs

Related patents

Number Title Jurisdiction
11834451 Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection US
10555997 Antigens and vaccines directed against human enteroviruses US
10548964 Antigens and vaccines directed against human enteroviruses US
9987350 Antigens and vaccines directed against human enteroviruses US
8524676 Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds US

Related hubs

FAQ

What is the TGA / PMDA / NMPA approval status of enterovirus?

enterovirus currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get enterovirus regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to enterovirus?

This spoke lists 7 published programs associated with enterovirus in our pipeline index.